Skip to content
Financial Reports
-
Syntegon reports 7% sales growth as pharma business drives the first-half 2026 results
The company reported group sales of EUR 883 million (US$1.03 billion), representing a 7 percent increase from the same period in 2025.
-
Everest Medicines reports 157% H1 2026 revenue surge to US$161.7M
The company recorded non-IFRS net profit of RMB 97.23 million (US$13.7 million), while its IFRS net loss narrowed 98% year-on-year. Everest ended the period with RMB 1.859 billion (US$261.8 million) in cash.